Cephalon Launches Takeover Bid For Australian Biotech Arana
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based biotech Arana Therapeutics announced Feb. 27 that Cephalon intends to make a cash takeover offer for all of Arana's shares at a price of $1.40 per share
You may also be interested in...
Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary
PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary
Cephalon Extends Deadline On Arana Buyout In Hopes Of Making The Aussie Biotech A Wholly Owned Subsidiary
PERTH, Australia - Cephalon International Holdings has extended its deadline to June 15 for its acquisition of Australian biotech Arana shares in hopes of gaining 90 percent control of the target company, and then transforming it into a wholly owned subsidiary
Cephalon Purchases Majority Stake In Australian Biotech Arana, Clearing Way For Full-scale Acquisition
PERTH, Australia - Through ongoing buying of shares in the target company, Cephalon International Holdings has achieved a controlling 50 percent-plus interest in Australian biotech Arana. Cephalon's offer to acquire Arana is now "free from all outstanding conditions," Cephalon announced May 20